What is Global Injectable for Cosmetic Surgery Market?
The Global Injectable for Cosmetic Surgery Market is a rapidly expanding sector within the healthcare industry. This market encompasses a variety of products used in cosmetic procedures to enhance or alter physical appearance. These injectables, which include substances like Botulinum Toxin, Soft Tissue Fillers, Dermal Fillers, and others, are used by professionals in the field to perform non-surgical aesthetic procedures. The market's value was estimated at US$ 45840 million in 2023, and it is projected to reach a staggering US$ 173000 million by 2030. This impressive growth, representing a CAGR of 20.6% during the forecast period 2024-2030, is indicative of the increasing demand for these products worldwide.
Botulinum Toxin, Soft Tissue Fillers, Dermal Fillers, Others in the Global Injectable for Cosmetic Surgery Market:
Botulinum Toxin, Soft Tissue Fillers, Dermal Fillers, and other injectables are key components of the Global Injectable for Cosmetic Surgery Market. Botulinum Toxin, more commonly known as Botox, is a neurotoxic protein used to reduce wrinkles and fine lines by temporarily paralyzing muscles. Soft Tissue Fillers, on the other hand, are substances designed to be injected beneath the skin to add volume and smoothness. Dermal Fillers are a type of soft tissue filler used to reduce facial lines and restore volume and fullness in the face. Other injectables used in cosmetic surgery include products like collagen stimulators and fat reducers. These products, each with their unique properties and uses, contribute to the diversity and versatility of the injectable cosmetic surgery market.
Hospitals, Dermatology Clinics, Beauty Centers, Othes in the Global Injectable for Cosmetic Surgery Market:
The Global Injectable for Cosmetic Surgery Market finds its applications in various settings such as Hospitals, Dermatology Clinics, Beauty Centers, and others. Hospitals and Dermatology Clinics are the primary users of these products, employing them in a range of cosmetic procedures from anti-aging treatments to reconstructive surgeries. Beauty Centers also make use of these injectables, offering non-surgical cosmetic procedures to their clients. Other settings where these products find use include private practices and wellness centers. The widespread usage of these products across different settings is a testament to their effectiveness and popularity.
Global Injectable for Cosmetic Surgery Market Outlook:
The future of the Global Injectable for Cosmetic Surgery Market looks promising. In 2023, the market was valued at US$ 45840 million. However, it is projected to skyrocket to US$ 173000 million by 2030, marking a CAGR of 20.6% during the forecast period 2024-2030. This growth is part of a larger trend in the medical devices market, which is estimated to be worth US$ 603 billion in 2023 and is expected to grow at a CAGR of 5% over the next six years. These figures highlight the increasing demand for injectable cosmetic surgery products and the potential for further growth in the market.
| Report Metric | Details |
| Report Name | Injectable for Cosmetic Surgery Market |
| Accounted market size in 2023 | US$ 45840 million |
| Forecasted market size in 2030 | US$ 173000 million |
| CAGR | 20.6% |
| Base Year | 2023 |
| Forecasted years | 2024 - 2030 |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | AbbVie, Galderma, LG Life Sciences, Merz, Medytox, HUGEL, Croma-Pharma, Beijing IMEIK, Bloomage Bio, Elravie (Humedix), Cleviel (Pharma Research Products), Haohai Biological, Q.O.Fill (JW Pharmaceutical), Teoxane, Sinclair, Suneva Medical, CG Bio, SciVision Biotech, Prollenium, Matex-Lab, Jingjia Medical, Genoss, Bohus BioTech, Caregen |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
